may al,;o reduce the hazards in man of chronic exposure to sllb-aJ1aesthetic doses of enflurane compared to halothane and methoxyflurane.
Enflurane metabolism at anaesthetic dosage in man, has been studied using the drug as the sole anaesthetic agent . However, in clinical practice, it is used most often as a supplement to nitrous oxide and oxygen anaesthesia.
The present study was designed to determine the degree of metabolism of enflurane to inorganic fluoride ion (F-) and to detect any nephrotoxicity when it is used at one half :\IAC as a supplement to relaxant nitrous oxide-oxygen anaesthesia. The study also examined the time course of clearance of the enflurane metabolite Ffollowing sub-anaesthetic doses of enflurane.
:\IETHOD 1\venty-six healthy male surgical patients, from whom an informed consent had been obtained, were randomly allocated to receive either enflurane or halothane. Patients with abnormalities in renal or hepatic function or Anaesthesia alld Intellsive Care, ral. 1·, Xo. 3, AUgltsl, 1977 undergoing surgery with possible renal complications were excluded from the study.
Pre-operatively, a full blood count and biochemical profile was performed on every patient. In particular, measurements were made of serum and urinary osmolality and sodium, potassium, uric acid, creatinine, urea and inorganic fluoride concentration. From the above, twenty-four hour urinary solute excretions and clearances were calculated. Prior to operation, overnight urine concentrating ability was determined by restricting all oral intake beginning at 6.00 p.m., emptying the bladder at 6.00 a.m. the next morning and measuring osmolality on the next urine specimen.
ANAESTHETIC TECHNIQUE Premedication consisted of intramuscular papaveratum 20 mg and hyoscine 0·4 mg per 70 kg given two hours prior to anaesthesia.
Anaesthesia was induced with a sleep dose of thiopentone. Pancuronium 1·0 mg per 10 kg was administered for intubation and muscle relaxation. Anaesthesia was maintained with nitrous oxide and oxygen at 5 and 2 litres per minute, respectively, into a semi-closed circle system with carbon dioxide absorption. After intubation and establishment of controlled ventilation, either halothane or enflurane was introduced. The inspired concentration was adjusted to give a mean alveolar concentration of approximately t MAC, i.e. 0·3 to 0·4 % for halothane and 0·6 to 0·7% for enflurane.
Anaesthetic dosage was defined by multiplying the mean alveolar concentration by the time of exposure (e.g. t MAC for 2 hours=l MAC hour).
Patients receiving enflurane were divided into three groups according to the duration of exposure as follows: Group I-t MAC for half-hour=! MAC hour Group II-t MAC for two hours=l MAC hour Group III-t MAC for four hours =2 MAC hours Group IV consisted of patients receiving t MAC halothane for between t to 4 MAC hours.
Intravenous thiopentone or narcotic was used if further supplementation was required following the cessation of the volatile agent.
Gas samples were obtained via a catheter placed at the lower end of the endotracheal tube for measurement of end-tidal (alveolar) anaesthetic concentration. Arterial blood samples were obtained during exposure to measure, pH, PC0 2 , P0 2 and anaesthetic concentration. Anaesthetic concentration III gas and blood was determined by gas chromatography using a Varian 1440 gas chromatograph with flame ionization detector, disc integrator and a 6' x1/8" O.D. stainless steel column packed with Porapak Q (Waters Associates).
The nitrogen carrier gas flow rate was 12-15 ml/min and the column temperature was 195°C.
Post-operatively, serum and urine biochemical measurements were made daily, as during' the the pre-operative period. Serum inorganic fluoride concentration also was measured at the cessation of supplement and at six hours, 24 hours and 48 hours post-anaesthesia. In addition, 24 hours following operation, all patients received a subcutaneous injection of 2·5 units vasopressin in oil; urine specimens were collected at approximately four hour intervals for 24 hours and osmolalites were determined in order to evaluate maximum urine concentrating ability.
FLUID THERAPY
Prior to anaesthesia, food and fluids were allowed ad libitum except when no oral intake was permitted while testing overnight urine concentrating ability and after midnight of the night preceding surgery. Upon arrival in the operating room, 10 ml/kg of body weight of Hartmann's Solution was administered intravenously, to all patients; all measured intra and post-operative fluid losses, plus an additional 700 ml/day for insensible fluid losses, were replaced with the above noted or similar salt containing intravenous solutions. Tusl (1972) has shown that the fluoride ionselective electrode, used with "TISAB" solution gives accurate results for measurement, of urinary F-without sample pre-treatment. We have used a modification of his procedure for the analysis of inorganic fluoride in serum and urine.
Determination of Inorganic Fluoride Concentration (F-)
A Philips digital ion activity meter (PW9414) and an Orion 94-09 fluoride electrode were used.
For urine F-analysis, to 2·0 ml of urine or standard solution was added 2 ·0 ml of " TISAB " buffer and metal complexing solution (57 ml glacial acetic acid, 58 g sodium chloride and 4 g cyclohexylene dinitrilo tetracetic acid adjusted to pH 5·4 with concentrated sodium hydroxide solution and made up to 1000 ml). The "TISAB" solution with its high ionic strength ([1.=2) raises the ionic strength of standard or urine solutions to approximately the same value (fL=I'O to 1'1) so that activity effects can be ignored and urinary F-can be read off a calibration plot of potential versus concentration.
The F-in pre-anaesthetic serum is very low (approximately 2 fLmolfl) and it was found that F-in distilled water and Analytical Reagent grade sodium chloride caused contamination problems at this low serum Fconcentration.
Accordingly, all standard solutions of less than 100 fLmolfl were made up in water that had been de-ionised and then distilled from alkaline permanganate. For serum analysis, in order to avoid excessive dilution, to 1·0 ml of serum or standard was added 0·1 ml of concentrated "TISAB", solution (57 ml glacial acetic acid and 4 g cyclohexylene dinitrilo tetracetic acid adjusted to pH 5· 4 with concentrated sodium hydroxide and made up to 100 ml). Although this solution did not contain sodium chloride as an ionic strength adjustor, it has a high ionic strength (fL~8) and brings sample and standard solutions up to similar high ionic strength value (fL~0'8 to 0·9). F-calibration curves were linear down to 1 fLmolfl and had a slope of 58 to 59 mv. Some analyses were checked by the method of standard additions (standard added to the sample matrix) and it was found that results agreed with the more rapid calibration curve procedure within 5-15 % even at serum Fof less than 10 fLmolfl. 
lated from the end of the first post-operative day. Student's " t " test was used for statistical analysis. Dose-response curves were also examined using regression analysis of preto post-operative changes in each variable plotted against anaesthetic dosage.
RESULTS
Pre-operatively the groups did not differ significantly except as might be expected to occur due to chance (Tables 1-4) . Post-operative results in Group IV (Halothane control group) did not show significant differences from the pre-operative results for all the groups. During anaesthesia, determination of P0 2 , PC0 2 and pH of arterial blood showed that all patients were adequately oxygenated and ventilated. Prior to surgical stimulation, adequate arterial blood pressures were maintained by infusion of intravenous Hartmann's solution in all groups.
Gas chromatographic analysis showed that the alveolar and blood enflurane concentrations (Table 1) were close to t MAC in each group. and Ill. However, Group Il and Group III levels were rapidly approaching control measurements (Figure 2 ). Urinary F-excretion reached peak values on the first day following enflurane anaesthesia; the highest mean value being 958 ±118 [Lmol!24 hours, in Group III (Table 2) . Urinary Fexcretion had fallen on the second post-operative :... day but the levels were still significantly higher than the pre-operative levels (Table 2) . Pooled F-excretions from the immediate post-operative period and the Day 1 post-operatively show a clear relationship between F-excretion and enflurane dosage (Figure 3 ).
MEAN URINARY F-EXCRETION -First post-operative day
Pre-operative UFV + all groups <80pm/day GP! GPD GPm (ENFLURANE 0-25 MAC HRS) * P<0'05 GPII VS GPl + P<005 GPm VS GPn Serum sodilim, potassium, creatinine, uric acid and osmolality were within normal limits for all groups, pre-and post-operatively, although serum osmolality tended to fall post-operatively in all groups (Table 3) . Table 4 shows the results of pre-and postoperative urinary solute excretions, urine volumes and creatinine clearances. Patients receiving enflurane did not show a significant difference from the control group (Table 4) ; the post-operative elevation of creatinine clearance in Group IV is within normal limits and is not indicative of renal dysfunction.
Increased urine volume in Group III was not associated with low urine osmolality and was consistent with excretion of a solute load administered during prolonged surgery.
The response to vasopressin was normal in all patients; maximum urine osmolalities were not significantly different from those obtained pre-operatively after overnight fasting (Table 5 ). This indicated that impairment of urine concentrating ability was not present III any group post-operatively. Regression analysis did not reveal significant correlations between anaesthetic dosage and any of the renal function variables measured for either halothane or enflurane.
DISCUSSION
In man (Cousins and Mazze 1973 ) and an animal model (Cousins et al. 1975 ) nephrotoxicity due to methoxyflurane has been demonstrated to be due to inorganic fluoride liberated by its metabolism. The serum F-threshold concentration of subclinical nephrotoxicity is approximately 50 f1.molfl. Exposure of Fischer 344 rats to enflurane (2,5%) for 6 to 10 hours has resulted in vasopressin resistant polyuria coinciding with similar serum F-concentration (Barr et al. 1974) . Further studies examined the potential of anaesthetic doses of enflurane to cause nephrotoxicity in man; Cousins et al. (1976) studied the metabolism of enflurane used as a sole inhalational anaesthetic agent. Exposure for a mean of 2·7±0·3 MAC hours produced a mean peak serum F-of 22·2±2·8 f1.molfl, occurring 4 hours after anaesthesia. Serum F-was generally not within the nephrotoxic range. A large individual variation in the degree of metabolism was noted and a dose-response relationship was not demonstrated.
The present study examines metabolism to inorganic fluoride (and renal effects) of subanaesthetic doses of enflurane. The drug is used as a supplement to N 2 0/muscle relaxants at half its MAC value for t, 2 and 4 hours, producing a dosage of 1, 1 and 2 MAC hours respectively; i.e. a mean arterial concentration of approximately 7 mg/100 ml maintained for 30 minutes, 60 minutes and 240 minutes respectively. With these dosages, which span the most common clinical range of use of enflurane, a nephrotoxic serum F-did not occur in any patient. The metabolism of sub-anaesthetic doses of enflurane to F-was directly related to the dose of anaesthetic (Figures 1 to 3) . Since the blood concentration of anaesthetic was maintained at the same level in each patient, in this study increases in dosage were determined by increased duration of anaesthesia. The urinary F-data ( Figure 3 ) indicate that increased duration of enflurane anaesthesia, at a constant sub-anaesthetic blood concentration, causes an increase in the dose of agent available for metabolism. Serum In Group Il, mean peak F-was 17·7 ±2·8 [lmol/l whereas in Group I mean peak F-was 10·5 ±O ·9 [lmol/l (Figure 1 ). It is possible that a plateau for serum F-may be reached with increasing duration of enflurane anaesthesia above 4 hours. The results of the present study do not provide a definitive answer for this question, however subsequent measurements of serum F-following 10 hours of enflurane anaesthesia at 1 MAC have been in the range 30-40 [lmol!l (Mazze et al. 1977) . It seems likely that the metabolism of enflurane at sub-anaesthetic doses will produce higher levels of serum F-with increasing exposure time, at least within the usual time limits of clinical practice.
Previous animal studies, (Barr, Cousins and Mazze 1974 ) employed enflurane at 1 MAC for six to ten hours (dosage 6 to 10 MAC hours) and these doses were associated with peak serum F-of 40-50 [lmol!l. This is quite close to the levels measured in man after It MAC for 10 hours (Mazze et al. 1977) . At this high dosage, the resultant serum F-is associated with significant polyuria in the animal model (Barr, Cousins and Mazze 1974) and man (Mazze et al. 1977) . However, the polyuria is very transient and is no longer detectable at 48 hours post anaesthesia. The time course of clearance of F-following enflurane was markedly different to that previously seen following methoxyflurane ( Figure  2) . Peak serum and urine F-occurred at cessation of enflurane in Groups I-Ill in this study. In contrast, peak serum F-following methoxyflurane is seen at approximately 24-48 hours post anaesthesia. In all three groups receiving enflurane in the present study, serum F-fell rapidly towards baseline levels by 48 hours post anaesthesia (Figure 2 ). Once again, this differed greatly from previous data for methoxyflurane which showed a sustained high level of serum F-at 72 hours post anaesthesia ( Figure 2 ) and at least another 72 hours was required to reach half this level (Cousins and Mazze 1973) . This data parallels the time course of polyuria following methoxyflurane compared to enflurane in the animal model. Thus, even after very high enflurane dosage, the parent drug and its metabolite F-are rapidly cleared and a briefly sustained nephrotoxic serum F-is associated with only transient polyuria. At usual clinical doses, employed in the present study, insufficient F-was produced to cause even transient abnormality in renal function. The present results are consistent with those of Cousins et al. (1976) ; the latter are included in Figure 2 for comparison of metabolism of similar total dosage to Group III but at anaesthetic blood levels. The rapid fall in urinary F-is also consistent with previous data of Norgate, Sharp and Cousins (1976) ; sub-anaesthetic doses of t MAC enflurane, with O 2 alone, for 2 hours resulted in urinary F-excretions (mean 176 [lmol!l) which were similar at 48 hours post exposure to those seen in the present study. In the previous study UFV was close to control levels by 5 days post exposure (Norgate et al. 1976) .
The metabolism data are supported by the results of renal function tests. The present study confirms that t MAC enflurane, administered for up to 4 hours, does not result in nephrotoxicity in patients with normal renal function. Absence of post-operative elevation of serum sodium, osmolality and creatinine (Table 3) together with normal creatinine clearances were taken as evidence of normal post-operative renal function. The normal Anaesthesia and Intensive Care, Vol. V, No. 3, August, 1977 B response to vasopressin is evidence that a renal concentrating defect was not present (Table 5) .
Less variation in individual defluorination is demonstrated in the current study than in the previous study using the agent" pure" . This may be due to: a more controlled eXPflsure, a greater number of patients studied, or a lower concentration of agent employed. Three patients received enflurane on more than one occasion, the intervals being one week, six weeks and eight weeks. The serum inorganic fluoride levels for each patient were remarkably consistent and showed no greater elevation on the second exposure. This is in keeping with previous studies of the metabolism of a second dose of enflurane (Norgate, Sharp and Cousins 1976) .
CONCLUSION
Enflurane used as a supplement at half MAC concentration was significantly metabolised to inorganic fluoride. The degree of metabolism reflected by serum F-and urinary F-excretion was related to the duration of exposure and, in turn, to total anaesthetic dosage (MAC hours).
A direct relationship between enflurane dosage in terms of MAC hours and metabolism to inorganic fluoride was present at the dosage range reported. This relationship was most readily seen in the immediate post-operative period.
Nephrotoxic serum concentrations of inorganic fluoride ion were not measured following these supplementary doses. However, at the highest dose (t MAC for 4 hours), the margin of safety is only approximately 2. It will be important to have further data which indicate whether this margin is adequate in patients with renal disease or when other nephrotoxic drugs are used concurrently; this is now compelling since recent animal data indicate that prolonged exposure of the kidney to F-results in toxicity at serUm F-as low as 20(lmoljl (Roman et al. 1977) .
